Trial record 4 of 3697 for:    Open Studies | radiotherapy

Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC) (CHISEL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by Trans-Tasman Radiation Oncology Group (TROG)
Information provided by (Responsible Party):
Trans-Tasman Radiation Oncology Group (TROG) Identifier:
First received: October 8, 2009
Last updated: January 22, 2015
Last verified: January 2015

The purpose of this study is to investigate whether radiotherapy given as three large doses over a period of two weeks (hypofractionated radiotherapy) is more effective than standard radiotherapy for patients with non-small cell lung cancer that has not spread beyond the lung. Although surgery is the most effective treatment for early lung cancer, many patients are not fit enough for an operation. The alternative treatment to surgery is standard radiotherapy which is normally 'fractionated' that is, given as a number of small doses over a period of weeks. Experience has shown that many small treatments are safer than using a few large doses (hypofractionation) because there is less risk of damage to normal tissues.

Recent advances in technology have however resulted in greater accuracy and with it a reduction in the amount of normal tissue affected by the radiation, so the risks of hypo-fractionation damaging normal tissue are of less concern. Initial results obtained with hypo-fractionated radiotherapy for early stage non-small cell lung cancer indicate that it may be more effective in controlling the cancer. However, it has never been compared directly with standard fractionation in a randomised trial, so this study aims to determine if hypo-fractionation is more effective, results in longer life expectancy and if it is just as safe as standard fractionation.

Condition Intervention Phase
Non Small Cell Lung Cancer
Radiation: Hypofractionated radiotherapy (HypoRT)
Radiation: Conventionally Fractionated Radiotherapy (ConRT)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised Phase III Trial of Highly Conformal Hypofractionated Image Guided ("Stereotactic") Radiotherapy (HypoRT) Versus Conventionally Fractionated Radiotherapy (ConRT) for Inoperable Early Stage I Non-small Cell Lung Cancer (CHISEL)

Resource links provided by NLM:

Further study details as provided by Trans-Tasman Radiation Oncology Group (TROG):

Primary Outcome Measures:
  • Time to Local Failure [ Time Frame: Completion of the two year follow up period for all patients. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Completion of the two year follow up period for all patients. ] [ Designated as safety issue: No ]
  • Cancer Specific survival [ Time Frame: Completion of the two year follow up period for all patients. ] [ Designated as safety issue: No ]
  • Treatment Related Toxicity [ Time Frame: Completion of the two year follow up period for all patients. ] [ Designated as safety issue: Yes ]
  • Quality of Life [ Time Frame: Completion of the two year follow up period for all patients. ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: December 2009
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 2
Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
Radiation: Conventionally Fractionated Radiotherapy (ConRT)
Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
Other Names:
  • ConRT
  • Radiotherapy
  • RT
Experimental: Arm 1
Hypofractionated radiotherapy (HypoRT) - Investigational
Radiation: Hypofractionated radiotherapy (HypoRT)
Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
Other Names:
  • HypoRT
  • Radiotherapy
  • RT

Detailed Description:

This is a multicentre randomised phase III trial comparing hypo-fractionated ("stereotactic') radiotherapy with conventional radiotherapy with or without chemotherapy in patients with inoperable stage 1 peripherally located non-small cell lung cancer.

The accepted standard of care for stage 1 non-small cell lung cancer (NSCLC), that is, T1 or T2 tumors that have not metastasised to the regional lymph nodes, is surgical resection. However, many patients with lung cancer have significant cardiovascular and respiratory co morbidities which render them unfit for an operation. For these patients, the standard of care is radiotherapy - conventional fractionation (ConRT) which is administered as 20-30 fractions over a period of four to six weeks. This reduces the likelihood of long term damage to incidentally irradiated normal tissues compared with non-fractionated treatment. Local failure for this method, varies considerably between reports ranging from 6-70% with a median value of 40% using a current best practice for inoperable NSCLC dose of about 60 Gy. Concomitant chemotherapy in addition to CF improves local progression free survival by 16% at two years compared with radiotherapy alone.

Highly conformal hypo-fractionated image guided radiotherapy is an emerging technically complex method for precision irradiation of stage 1 NSCLC using doses with a higher biological effect than can be achieved with standard treatment techniques. Although rates of local control using hypo-fractionation appear greater, there are risks with serious late toxicity. However, there is recent evidence that 54-57Gy delivered in 3 fractions can be delivered safely with no excessive toxicity, provided the tumour has a peripheral location, the chest wall is not included in the high dose volume and the treatment plan is highly conformal. Although hypo-fractionation under the above conditions appears to be tolerable, and is associated with high levels of local control, the results of a small number of phase II trials cannot be regarded as sufficient evidence to recommend it as the standard of care for inoperable stage I NSCLC.

This randomised phase III trial tests whether highly conformal hypo-fractionated image guided radiotherapy for peripherally located inoperable T1 and T2a NSCLC using a dose of 54 Gy in three fractions results in superior control of disease at the primary site compared with standard care consisting of conventionally fractionated radiotherapy with or without concomitant chemotherapy.

Treatment summary: Investigational arm - radical radiotherapy to a total dose of 54 Gy in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed. Conventional arm - radical radiotherapy to a total dose of 60-66 Gy in 30-33 daily 2 Gy fractions over 6 weeks, with or without chemotherapy consisting of weekly carboplatin at an AUC of 2 and paclitaxel 45 mg/m2.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer diagnosed within 6 weeks prior to randomisation. The following primary cancer types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioloalveolar cell carcinoma, large cell neuroendocrine, and non-small cell carcinoma not otherwise specified.
  • Aged 18 years or older.
  • Disease stage T1N0 or T2aN0 (UICC TNM stage, 7th Ed, 2009), based on FDG PET/CT performed within 4-6 weeks prior to randomisation. T stage should be based on tumour size alone (i.e. no atelectasis).
  • An ECOG performance status score of 0 or 1.
  • The tumour has a peripheral location, defined as at least 1 cm beyond the mediastinum and 2 cm beyond the bifurcation of the lobar bronchi.
  • Tumour is assessed as inoperable either i) because of unfitness for surgery as determined by the lung multidisciplinary team including thoracic surgeons and respiratory physicians or ii) because the patient refuses surgery.
  • Female patients of childbearing potential and male patients must agree to use adequate contraception throughout the treatment phase of the study.
  • If female and of childbearing potential, a negative pregnancy test was performed within 7 days prior to randomisation.
  • Patient is expected to survive and be available for follow up for two years.
  • Patient has provided written informed consent for participation in this trial prior to any protocol-specified procedures.
  • Patient undergoing chemoradiation has satisfactory haematological and biochemical parameters as described below:

    • ANC ≥ 1.5 x 109,
    • Platelets ≥ 100 x 109/L, Hb ≥ 100g/L,
    • Creatinine clearance ≥ 40mls/min (patients with calculated creatinine clearance ≥ 40mls/min and < 60mls/min must have this confirmed by nuclear medicine GFR scan),
    • Bilirubin < 1.5 x ULN, and
    • ALT or AST < 2x ULN.

Exclusion Criteria:

  • Centrally located tumours (< 1.0 cm from mediastinum or < 2.0 cm from bifurcation of lobar bronchus).
  • Tumours within 1.0 cm of the chest wall.
  • Prior chemotherapy.
  • Previous radiotherapy to the area to be treated.
  • Women who are pregnant or lactating.
  • Patient with multiple synchronous primary tumours requiring radiotherapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01014130

Contact: CHISEL Central Trial Coordinator +61 3 9656 1809

Australia, Australian Capital Territory
Canberra Hospital Recruiting
Canberra, Australian Capital Territory, Australia
Contact: Angela Rezo, Dr         
Principal Investigator: Angela Rezo, Dr         
Australia, New South Wales
Royal Prince Alfred Hospital Recruiting
Camperdown, New South Wales, Australia, 2050
Principal Investigator: Mo Mo Tin         
Liverpool Hospital Recruiting
Liverpool, New South Wales, Australia, 1871
Contact: Shalini Vinod    +61 2 9828 5276   
Calvary Mater Hosipital Recruiting
Newcastle, New South Wales, Australia, 2289
Principal Investigator: Jane Ludbrook         
Prince of Wales Hospital Recruiting
Randwick, New South Wales, Australia, 2031
Principal Investigator: Wenchang Wong         
Royal North Shore Hospital Recruiting
Sydney, New South Wales, Australia, 2069
Principal Investigator: Thomas Eade         
Australia, Queensland
Princess Alexandra Hospital Recruiting
Woolloongabba, Queensland, Australia, 4102
Principal Investigator: Tao Mai         
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia, 5000
Principal Investigator: Hie Le         
Australia, Tasmania
Royal Hobart Hospital Recruiting
Hobart, Tasmania, Australia, 7000
Principal Investigator: Marketa Skala         
Australia, Victoria
Peter MacCallum Cancer Centre Recruiting
East Melbourne, Victoria, Australia, 3002
Contact: David Ball, MB BS, MD, FRANZCR    +61 3 9656 1111   
Principal Investigator: Daivd Ball         
Principal Investigator: David Ball, Prof         
Austin Hospital Recruiting
Heidelburg, Victoria, Australia
Principal Investigator: Adeline Lim         
Peter MacCallum Cancer Centre - Box Hill Recruiting
Melbourne, Victoria, Australia, 3128
Principal Investigator: Andrew Wirth         
Peter MacCallum Cancer Centre - Morrabbin Recruiting
Melbourne, Victoria, Australia, 3165
Principal Investigator: Greg Wheeler         
Alfred Hospital Recruiting
Prahran, Victoria, Australia, 3181
Principal Investigator: Jeremy Ruben         
Australia, Western Australia
Sir Charles Gairdner Hospital Not yet recruiting
Nedlands, Western Australia, Australia, 6009
Principal Investigator: Sean Bydder         
Sponsors and Collaborators
Trans-Tasman Radiation Oncology Group (TROG)
Study Chair: David Ball, MB BS, MD, FRANZCR Peter MacCallum Cancer Centre, Australia
  More Information

Additional Information:
No publications provided

Responsible Party: Trans-Tasman Radiation Oncology Group (TROG) Identifier: NCT01014130     History of Changes
Other Study ID Numbers: TROG 09.02
Study First Received: October 8, 2009
Last Updated: January 22, 2015
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Trans-Tasman Radiation Oncology Group (TROG):
Non Small Cell Lung Cancer
Stereotactic Radiotherapy

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on July 30, 2015